142 related articles for article (PubMed ID: 33042633)
1. A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer.
Sohal D; Krishnamurthi S; Tohme R; Gu X; Lindner D; Landowski TH; Pink J; Radivoyevitch T; Fada S; Lee Z; Shepard D; Khorana A; Saunthararajah Y
Am J Cancer Res; 2020; 10(9):3047-3060. PubMed ID: 33042633
[TBL] [Abstract][Full Text] [Related]
2. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.
Molokie R; Lavelle D; Gowhari M; Pacini M; Krauz L; Hassan J; Ibanez V; Ruiz MA; Ng KP; Woost P; Radivoyevitch T; Pacelli D; Fada S; Rump M; Hsieh M; Tisdale JF; Jacobberger J; Phelps M; Engel JD; Saraf S; Hsu LL; Gordeuk V; DeSimone J; Saunthararajah Y
PLoS Med; 2017 Sep; 14(9):e1002382. PubMed ID: 28880867
[TBL] [Abstract][Full Text] [Related]
3. A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies.
Hill B; Jagadeesh D; Pohlman B; Dean R; Parameswaran N; Chen J; Radivoyevitch T; Morrison A; Fada S; Dever M; Robinson S; Lindner D; Smith M; Saunthararajah Y
Semin Hematol; 2021 Jan; 58(1):35-44. PubMed ID: 33509441
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
Tang Z; Liu L; Borlak J
Clin Epigenetics; 2023 May; 15(1):89. PubMed ID: 37208732
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.
Lau H; Woost PG; Friedrich U; Clausen WHO; Jacobberger JW; Saunthararajah Y
Eur J Haematol; 2023 Sep; 111(3):345-355. PubMed ID: 37417197
[TBL] [Abstract][Full Text] [Related]
6. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.
Lavelle D; Vaitkus K; Ling Y; Ruiz MA; Mahfouz R; Ng KP; Negrotto S; Smith N; Terse P; Engelke KJ; Covey J; Chan KK; Desimone J; Saunthararajah Y
Blood; 2012 Feb; 119(5):1240-7. PubMed ID: 22160381
[TBL] [Abstract][Full Text] [Related]
7. High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.
Ebrahem Q; Mahfouz RZ; Ng KP; Saunthararajah Y
Oncotarget; 2012 Oct; 3(10):1137-45. PubMed ID: 23087155
[TBL] [Abstract][Full Text] [Related]
8. Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.
Terse P; Engelke K; Chan K; Ling Y; Sharpnack D; Saunthararajah Y; Covey JM
Int J Toxicol; 2014; 33(2):75-85. PubMed ID: 24639139
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase.
Ferraris D; Duvall B; Delahanty G; Mistry B; Alt J; Rojas C; Rowbottom C; Sanders K; Schuck E; Huang KC; Redkar S; Slusher BB; Tsukamoto T
J Med Chem; 2014 Mar; 57(6):2582-8. PubMed ID: 24520856
[TBL] [Abstract][Full Text] [Related]
11. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
[TBL] [Abstract][Full Text] [Related]
12. Epimer interconversion, isomerization, and hydrolysis of tetrahydrouridine: implications for cytidine deaminase inhibition.
Xiang TX; Niemi R; Bummer P; Anderson BD
J Pharm Sci; 2003 Oct; 92(10):2027-39. PubMed ID: 14502542
[TBL] [Abstract][Full Text] [Related]
13. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Savona MR; Odenike O; Amrein PC; Steensma DP; DeZern AE; Michaelis LC; Faderl S; Harb W; Kantarjian H; Lowder J; Oganesian A; Azab M; Garcia-Manero G
Lancet Haematol; 2019 Apr; 6(4):e194-e203. PubMed ID: 30926081
[TBL] [Abstract][Full Text] [Related]
14. Mycoplasma infection of cancer cells enhances anti-tumor effect of oxidized methylcytidines.
Pang GZ; Zhao YH; Wang YX; Rong SQ; Gao H; Zhou D
Biochem Biophys Res Commun; 2023 Sep; 672():193-200. PubMed ID: 37356286
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase.
Kim CH; Marquez VE; Mao DT; Haines DR; McCormack JJ
J Med Chem; 1986 Aug; 29(8):1374-80. PubMed ID: 3735306
[TBL] [Abstract][Full Text] [Related]
16. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Saunthararajah Y; Sekeres M; Advani A; Mahfouz R; Durkin L; Radivoyevitch T; Englehaupt R; Juersivich J; Cooper K; Husseinzadeh H; Przychodzen B; Rump M; Hobson S; Earl M; Sobecks R; Dean R; Reu F; Tiu R; Hamilton B; Copelan E; Lichtin A; Hsi E; Kalaycio M; Maciejewski J
J Clin Invest; 2015 Mar; 125(3):1043-55. PubMed ID: 25621498
[TBL] [Abstract][Full Text] [Related]
18. Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Parise RA; Egorin MJ; Eiseman JL; Joseph E; Covey JM; Beumer JH
Rapid Commun Mass Spectrom; 2007; 21(13):1991-7. PubMed ID: 17526067
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Laliberté J; Marquez VE; Momparler RL
Cancer Chemother Pharmacol; 1992; 30(1):7-11. PubMed ID: 1375134
[TBL] [Abstract][Full Text] [Related]
20. Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
Besnard T; Renée N; Etienne-Grimaldi MC; François E; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(1):117-20. PubMed ID: 18562256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]